A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

To join this study, you would need to have a confirmed diagnosis of advanced high-grade ovarian, primary peritoneal, or fallopian tube cancer. Crucially, your cancer must also have been resistant to previous platinum-based chemotherapy treatments. This means your cancer either started growing again relatively soon after treatment, or didn't respond adequately.

Your cancer cells also need to have a high amount of a specific protein called Folate Receptor Alpha (FRα). Doctors will check for this with a special test on your tumor tissue. You should also generally be well enough to take part in a study like this, as assessed by your doctor, and have at least one measurable tumor that can be tracked during the study.

Hover, you would not be able to join if you have certain other types of ovarian cancer (like endometrioid, clear cell, or mucinous) or if your cancer never responded to your first platinum chemotherapy. Certain serious health conditions or a recent stroke would also prevent you from participating.

If you decide to take part in this study, it would involve regular visits to a hospital or clinic over approximately two years. During these visits, you will have frequent medical check-ups, which may include physical exams, blood tests, and scans (like CT or MRI scans) to monitor your health and how the treatment is affecting your cancer. You would receive the study medication, Mirvetuximab Soravtansine, through a drip into your vein (intravenously).

There are two main groups in the study. In one group, you would receive the medication on a specific schedule, either once every three weeks or twice every four weeks. The other group looks at how the drug works for people with certain liver conditions. It's important to know that taking part in a study often means more appointments and tests than your usual care, but this helps the doctors monitor your health very closely. You will be fully informed about the specific schedule and what to expect before you agree to join.